Patients with endocrine-resistant HR-positive/HER2-negative metastatic breast cancer require novel therapeutic alternatives as a result of the poor outcomes of currently available later-line medications.
The emergence of innovative targeted therapy in combination with endocrine therapy has shown improvement in HR-positive breast cancer results, but the US Food and Drug Administration–approved combinations all include endocrine therapies in their regimens, leaving an unmet need in patients who develop endocrine resistance.
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice
Each year, approximately 250,000 cases of breast cancer are diagnosed in the United States.
The phase 3 OlympiA trial showed olaparib had impressive results versus placebo, with improvement in disease-free survival with adjuvant olaparib in early-stage, HER2-negative breast cancer and BRCA1/2 mutations. This highlights the need to test for BRCA1/2 mutations to determine if patients qualify for olaparib.
A recent study found that omega-6 PUFA supplementation surprisingly reduced cancer-related fatigue in exhausted American breast cancer survivors when compared with omega-3 PUFA supplementation, and that omega-6 PUFA supplementation surprisingly lowered proinflammatory blood markers, completely against expectations.
A Web-Based Survey on Suggested Modifications in the Management of Patients with Breast Cancer During the COVID-19 Pandemic
Results of a recent web-based survey show that survey respondents are in favor of several changes in breast cancer treatment during COVID-19. These changes must be discussed on a local level, taking into consideration the infrastructure and resources available.
Real-World Patient-Reported Outcomes, Clinical Profile, and Treatment Patterns in a Subset of Patients with HR-Positive, HER2-Negative, Advanced Breast Cancer with Poor Prognostic Factors
In a real-world study, more than 60% of the HR-positive, HER2-negative advanced breast cancer samples had ≥1 disease-related poor prognostic factors. The need for more effective CDK4/6 inhibitor medication in these individuals is highlighted by their increased pain and impaired performance status.
Overall Survival in Patients with HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer Treated with a CDK4/6 Inhibitor plus Fulvestrant: An FDA Pooled Analysis
Adding CDK4/6 inhibitors to fulvestrant resulted in an improvement in overall survival. These findings back up the current standard of care of CDK4/6 inhibitors plus fulvestrant for patients with HR-positive, HER2-negative, advanced breast cancer.
Page 1 of 20
Results 1 - 10 of 197
Results 1 - 10 of 197